Vera Zherebtsova

Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma

Vânia Hungria, Paweł Robak, Marek Hus et al. · New England Journal of Medicine · 2024 · 166 citations

Medicine, Pharmacology, Pharmacotherapy +13

Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib

Elias Jabbour, Vivian G. Oehler, Paul Koller et al. · JAMA Oncology · 2024 · 27 citations · Full text

Medicine, Oncology, Pharmacology +14

Results from the randomized phase III DREAMM-7 study of belantamab mafodotin (belamaf) + bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM).

María‐Victoria Mateos, Paweł Robak, Marek Hus et al. · Journal of Clinical Oncology · 2024 · 21 citations

Medicine, Pharmacology, Pharmacotherapy +15

Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial

Vânia Hungria, Paweł Robak, Marek Hus et al. · The Lancet Oncology · 2025 · 16 citations

Medicine, Pharmacology, Pharmacotherapy +11

Epidemiology of multiple myeloma in city Moscow

Olga Vinogradova, M. V. Chernikov, Yu. B. Kochkareva et al. · Terapevticheskii arkhiv · 2019 · 15 citations · Full text

Medicine, Hematology, Internal Medicine +13